☆
Watchlist
Log in
Sign-up
Alterity Therapeutics Ltd (ath) Logo

Alterity Therapeutics Ltd (ATH)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

ATH Chart

Snapshot

ATH's Principal Activity is the commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -31.79%
vs ASX 200 (1yr) -35.88%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,405 of 2,411
Sector Rank -

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies -
EPS -$0.005
DPS $0.00
Book Value Per Share $0.01

Broker Consensus

ATH is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an Australian biotechnology company which focusses to commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.

Incorporation Details

Incorporated in VIC on 11/11/1997 as Prana Corporation Pty Ltd. Incorporation status changed to "Limited" on 26/11/1999. Name changed to Prana Biotechnology Limited on 05/01/2000.

Corporate Details

Head Office Melbourne VIC 3000
Website www.alteritytherapeutics.com
Registry Computershare
Auditor PricewaterhouseCoopers
Date Listed 28 Mar 2000

Upcoming Calendar (Forecasted)

Date Event
31/08/2022 Report (Prelim)
31/08/2022 Report (Annual)
27/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr David Stamler Chief Executive Officer Jan 2021
Mr Phillip Hains Company Secretary May 2014
Mr Lawrence Gozlan Non-Executive Director Aug 2011

Mr Lawrence Gozlan

Non-Executive Director

Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a investment fund which has focus in life sciences. Prior to this, Mr Gozlan was in charge for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"). He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr Gozlan is currently direcor of number of private biotechnology companies in the USA.
Mr Peter Ashley Marks Non-Executive Director Jul 2005

Mr Peter Ashley Marks

Non-Executive Director

Mr Marks for over 13 years until the end of August 2014 was a Director of Peregrine Corporate Ltd, an Australian-based investment banking and corporate advisory firm. Mr Marks was until 2016, a Director of Armadale Capital Plc, which has focus on natural resources projects based in Africa with its current investments being a gold exploration company in DRC and a coal briquetting operation in South Africa. Mr Marks is currently a Consultant at Henslow Pty Ltd, a corporate and capital markets advisory firm. Mr. Marks is also a nonexecutive director of Terragenic International Ltd, an unlisted public company and has develop a novel hydrogen fuel system. From September 1998 until March 2001, Mr Marks was working with KPMG Corporate Finance Ltd (Australia), where he rose to Director and was in charge for heading up the equity capital markets group in Melbourne. From January 1992 until July 1994, Mr. Marks served as Head of the Melbourne Companies Department at the ASX and was founding Director of Momentum Funds Management Pty Ltd, an Australian venture capital firm. From December 1990 until December 1991, Mr Marks served as Director of Corporate Finance at Burdett Buckeridge & Young Ltd in their Melbourne offices, from August 1988 until November 1990, he held senior corporate finance position at Barings Securities Ltd, and from July 1985 until July 1988, he served as an Associate Director of McIntosh Securities, now Merrill Lynch Australia. In his roles with these financial institutions, Mr Marks was in charge for advising a number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.
Mr Geoffrey Paul Kempler Non-Executive Chairman,Non-Executive Director Jun 2005

Mr Geoffrey Paul Kempler

Non-Executive Chairman,Non-Executive Director

Mr Kempler has served as our Chief Executive Officer, and in June 2005 he again assumed the position of Chief Executive Officer. Mr Kempler has experience in investment and business development, has been in charge for the implementation of our strategic plan and the commercialisation of our technology.
Mr Brian Derek Meltzer Non-Executive Director Dec 1999

Mr Brian Derek Meltzer

Non-Executive Director

Mr Meltzer spent 25 years in investment banking. His breadth of expertise includes property transactions, corporate advisory, corporate finance, management buyouts, venture capital and syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health, aged care, software, entertainment and finance sectors, including Director of a federal government Innovation Investment Fund. Mr Meltzer is also a Director of the Australia-Israel Chamber of Commerce, Chairman of Independence Australia and Chairman of a privately owned corporate health and wellness business.
David Stamler Chief Executive Officer N/A
Show All

Director Transactions

ATH directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
18/09/20 Tristan Edwards Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Peter Marks Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Lawrence Gozlan Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Geoffrey Kempler Issued 14,000,000 $0.054 $756,000 Issue of options
18/09/20 David Sinclair Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Brian Meltzer Issued 7,000,000 $0.054 $378,000 Issue of options
Show All

Director Interests

The current holdings of ATH directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Lawrence Gozlan 30/06/2021 N/A N/A 8,250,000 N/A
Peter Marks 30/06/2021 43,111 N/A 8,250,000 N/A
Brian Meltzer 30/06/2021 326,666 N/A 8,250,000 N/A
Geoffrey Kempler 30/06/2021 30,000 17,981,000 19,000,000 N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Jun 30, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 1,358,556,242 56.44%
Life Biosciences Llc 269,905,533 11.21%
Jagen Pty Ltd 38,556,497 1.60%
1215 Capital Pty Ltd 18,733,028 0.78%
Rentuk Shore Pty Ltd 15,641,719 0.65%
Capuano Nominees Pty Ltd (The Hartman Investment A/C) 15,000,000 0.62%
Andrew Mark Wilmot Seton 14,795,663 0.61%
Citicorp Nominees Pty Limited 14,394,030 0.60%
Baywick Proprietary Limited (The Retail Discretionary A/C) 14,165,000 0.59%
BNP Paribas Nominees Pty Ltd Acf Clearstream 12,164,297 0.51%
Fagan Harris Pty Ltd (Fagan Harris Super Fund A/C) 9,500,000 0.39%
Mr Benjamin Woolvett 7,210,000 0.30%
Mr Bill Konstad & Mrs Despina Konstad (The B&D Konstad S F Ac) 6,195,856 0.26%
Mr David John Southon (Southon Family A/C) 6,000,000 0.25%
Mr Minh Huy Lam 6,000,000 0.25%
Mr Huy Nguyen (Huy Nguyen Super Fund A/C) 5,380,195 0.22%
Mr Anurag Pandey 5,020,000 0.21%
Citos Super Pty Ltd (Citos Pty Ltd Sf A/C) 5,000,000 0.21%
Mr Christopher Robert Schroeter 4,778,958 0.20%
Donatello Nizzi 4,678,362 0.19%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 508 1,175 586 2,580 1,018 5,867

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Life Biosciences LLC 18/03/2022 243,396,873 10.10
The Bank of New York Mellon Corporation 02/05/2022 1,422,723,388 59.11

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
15-03-22 The Bank of New York Mellon Corporation 259,216,860 49.42 60.19
09-07-21 The Bank of New York Mellon Corporation 48,300,000 56.16 58.17
07-07-21 The Bank of New York Mellon Corporation 325,257,900 42.65 56.16
06-07-21 The Bank of New York Mellon Corporation 68,395,500 39.81 42.65
02-07-21 The Bank of New York Mellon Corporation 11,361,960 45.43 39.81
28-06-21 The Bank of New York Mellon Corporation 20,975,520 44.42 45.43

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
02-05-22 The Bank of New York Mellon Corporation 25,891,740 60.2 59.11
18-03-22 Life Biosciences LLC 26,508,660 11.2 10.10
20-01-22 The Bank of New York Mellon Corporation 24,730,260 50.4 49.42
05-01-22 The Bank of New York Mellon Corporation 27,103,020 51.6 50.44
20-12-21 The Bank of New York Mellon Corporation 26,904,480 52.7 51.57
02-12-21 The Bank of New York Mellon Corporation 24,720,180 53.7 52.69
22-11-21 The Bank of New York Mellon Corporation 30,656,100 55.0 53.72
01-11-21 The Bank of New York Mellon Corporation 26,375,640 56.1 54.99
30-08-21 The Bank of New York Mellon Corporation 26,036,220 57.2 56.08
10-08-21 The Bank of New York Mellon Corporation 24,126,660 58.2 57.17

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.027 30 June
2020 $0.017 30 June
2019 $0.029 28 June
ATH Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.